▶Disulfiramis predicted to increase the anticoagulant effect of
phenindione.rTheoretical
Dobutamine→see sympathomimetics, inotropic
Docetaxel→see taxanes
Dolutegravir
▶Antacidsmoderately decrease the exposure todolutegravir.
Dolutegravirshould be taken 2 hours before or 6 hours after
antacids.oStudy
▶Antiepileptics(carbamazepine, fosphenytoin, phenobarbital,
phenytoin, primidone)decrease the exposure todolutegravir.
Adjust dose.rStudy
▶Antiepileptics(oxcarbazepine)are predicted to decrease the
exposure todolutegravir. Adjust dose.rTheoretical
▶Bosentandecreases the exposure todolutegravir. Adjust dose.
rStudy
▶Oralcalcium saltsdecrease the absorption ofdolutegravir.
Dolutegravirshould be taken 2 hours before or 6 hours after
calcium salts.oStudy
▶Efavirenzdecreases the exposure todolutegravir. Adjust dose.
rStudy
▶Enzalutamidedecreases the exposure todolutegravir. Adjust
dose.rStudy
▶Etravirinemoderately decreases the exposure todolutegravir.
Avoid unless given with atazanavir, darunavir, or lopinavir (all
boosted with ritonavir).rStudy
▶HIV-protease inhibitors(fosamprenavirboosted with ritonavir)
slightly decrease the exposure todolutegravir. Avoid if
resistant to HIV-integrase inhibitors.rStudy
▶HIV-protease inhibitors(tipranavir)moderately decrease the
exposure todolutegravir. Refer to specialist literature.r
Study
▶Iron (oral)decreases the absorption ofdolutegravir.
Dolutegravirshould be taken 2 hours before or 6 hours after
iron (oral).oStudy
▶Dolutegravirslightly to moderately increases the exposure to
metformin. Use with caution and adjust dose.rStudy
▶Mitotanedecreases the exposure todolutegravir. Adjust dose.
rStudy
▶Nevirapinedecreases the exposure todolutegravir. Adjust
dose.rStudy
▶Rifampicindecreases the exposure todolutegravir. Adjust
dose.rStudy
▶St John’s Wortdecreases the exposure todolutegravir. Adjust
dose.rStudy
▶Sucralfatedecreases the absorption ofdolutegravir.o
Study
Domperidone→seeTABLE 9p. 849 (QT-interval prolongation)
▶Antiarrhythmics(dronedarone)increase the risk of QT-
prolongation when given withdomperidone. Avoid.r
Study
▶Antifungals, azoles(fluconazole, isavuconazole, itraconazole,
ketoconazole, posaconazole, voriconazole)increase the risk of
QT-prolongation when given withdomperidone. Avoid.r
Study
▶Aprepitantincreases the risk of QT-prolongation when given
withdomperidone. Avoid.rStudy
▶Calcium channel blockers(diltiazem, verapamil)increase the risk
of QT-prolongation when given withdomperidone. Avoid.
rStudy
▶Cobicistatincreases the risk of QT-prolongation when given
withdomperidone. Avoid.rStudy
▶Crizotinibincreases the risk of QT-prolongation when given
withdomperidone. Avoid.rStudy
▶Domperidoneis predicted to decrease the prolactin-lowering
effect ofdopamine receptor agonists(bromocriptine,
cabergoline).oTheoretical
▶HIV-protease inhibitorsincrease the risk of QT-prolongation
when given withdomperidone. Avoid.rStudy
▶Idelalisibincreases the risk of QT-prolongation when given
withdomperidone. Avoid.rStudy
▶Imatinibincreases the risk of QT-prolongation when given
withdomperidone. Avoid.rStudy
▶Macrolides(clarithromycin, erythromycin)increase the risk of
QT-prolongation when given withdomperidone. Avoid.r
Study
▶Netupitantincreases the risk of QT-prolongation when given
withdomperidone. Avoid.rStudy
▶Nilotinibincreases the risk of QT-prolongation when given
withdomperidone. Avoid.rStudy
Donepezil→see anticholinesterases, centrally acting
Dopamine→see sympathomimetics, inotropic
Dopamine receptor agonists→seeTABLE 8p. 848 (hypotension),
TABLE 9p. 849 (QT-interval prolongation),TABLE 10p. 849
(antimuscarinics)
amantadine.apomorphine.bromocriptine.cabergoline.pergolide
.pramipexole.quinagolide.ropinirole.rotigotine..FOOD AND LIFESTYLEDose adjustment might be necessary if
smoking started or stopped during treatment withropinirole.
▶Amisulprideis predicted to decrease the effects ofdopamine
receptor agonists. Avoid.oTheoretical→Also seeTABLE 9
p. 849
▶Antiarrhythmics(dronedarone)are predicted to increase the
exposure tobromocriptine.rTheoretical
▶Antiarrhythmics(dronedarone)are predicted to increase the
concentration ofcabergoline.rAnecdotal
▶Antifungals, azoles(fluconazole, isavuconazole, itraconazole,
ketoconazole, posaconazole, voriconazole)are predicted to
increase the concentration ofcabergoline.oAnecdotal
▶Antifungals, azoles(fluconazole, isavuconazole, posaconazole)
are predicted to increase the exposure tobromocriptine.
rTheoretical
▶Antifungals, azoles(itraconazole, ketoconazole, voriconazole)
increase the exposure tobromocriptine.rStudy
▶Aprepitantis predicted to increase the exposure to
bromocriptine.rTheoretical
▶Aprepitantis predicted to increase the concentration of
cabergoline.oAnecdotal
▶Aripiprazoleis predicted to decrease the effects ofdopamine
receptor agonists.oTheoretical→Also seeTABLE 8p. 848
▶Asenapineis predicted to decrease the effects ofdopamine
receptor agonists. Adjust dose.oTheoretical→Also see
TABLE 8p. 848
▶Benperidolis predicted to decrease the effects ofdopamine
receptor agonists. Avoid.oTheoretical→Also seeTABLE 8
p. 848
▶Bupropionincreases the risk of side-effects when given with
amantadine.oStudy
▶Calcium channel blockers(diltiazem, verapamil)are predicted to
increase the exposure tobromocriptine.rTheoretical→
Also seeTABLE 8p. 848
▶Calcium channel blockers(diltiazem, verapamil)are predicted to
increase the concentration ofcabergoline.o
Anecdotal→Also seeTABLE 8p. 848
▶Clozapineis predicted to decrease the effects ofdopamine
receptor agonists.oTheoretical→Also seeTABLE 8
p. 848→Also seeTABLE 10p. 849
▶Cobicistatincreases the exposure tobromocriptine.r
Study
▶Cobicistatis predicted to increase the concentration of
cabergoline.oAnecdotal
▶Combined hormonal contraceptivesare predicted to increase
the exposure toropinirole. Adjust dose.oStudy
▶Crizotinibis predicted to increase the exposure to
bromocriptine.rTheoretical
▶Crizotinibis predicted to increase the concentration of
cabergoline.oAnecdotal
▶Domperidoneis predicted to decrease the prolactin-lowering
effect ofdopamine receptor agonists(bromocriptine,
cabergoline).oTheoretical
▶Dopamine receptor agonists(cabergoline)are predicted to
increase the risk of ergotism when given withdopamine
receptor agonists(bromocriptine). Avoid.oTheoretical→
Also seeTABLE 8p. 848
▶Dopamine receptor agonists(bromocriptine, cabergoline)are
predicted to increase the risk of ergotism when given with
dopamine receptor agonists(pergolide). Avoid.o
Theoretical→Also seeTABLE 8p. 848
▶Dopamine receptor agonists(amantadine)are predicted to
increase the exposure todopamine receptor agonistsBNFC 2018 – 2019 Disulfiram—Dopamine receptor agonists 911
Interactions|Appendix 1A1